Nirmal Bang sees 41% upside in Zota Healthcare on faster store breakeven
Brokerage maintains Buy with Rs 1,795 target, citing ~15-month store breakeven (vs 18-24), 60% revenue CAGR and 227% Ebitda CAGR through FY28E as store maturity and operating leverage lift ROE to 12.5% and ROCE to 11.1%.
Nirmal Bang maintains Buy on Zota Healthcare with Rs 1,795 target (41% upside), citing faster store breakeven at ~15 months, expected 60% revenue CAGR and improving ROE/ROCE through FY28E from store maturity and operating leverage.
Why this matters
Brokerage conviction rests on accelerated unit economics: Zota's store breakeven has compressed to 15 months, unlocking a 60% revenue and 227% Ebitda CAGR trajectory through FY28E.
Retail-company signals steady at 3,173 over the last 90 days.